{"id":432,"date":"2026-08-15T04:01:27","date_gmt":"2026-08-15T04:01:27","guid":{"rendered":"http:\/\/www.imagerie-medicale-95.fr\/pharmacie\/?p=432"},"modified":"2026-08-15T04:01:27","modified_gmt":"2026-08-15T04:01:27","slug":"lagence-americaine-du-medicament-approuve-orzeyful-un-nouveau-traitement-contre-la-narcolepsie-de-type-1","status":"publish","type":"post","link":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/lagence-americaine-du-medicament-approuve-orzeyful-un-nouveau-traitement-contre-la-narcolepsie-de-type-1\/","title":{"rendered":"L\u2019agence am\u00e9ricaine du m\u00e9dicament approuve Orzeyful, un nouveau traitement contre la narcolepsie de type 1"},"content":{"rendered":"

L\u2019Agence am\u00e9ricaine des produits alimentaires et m\u00e9dicamenteux (FDA) a autoris\u00e9 la commercialisation d\u2019Orzeyful (ov\u00e9porexton), d\u00e9velopp\u00e9 par Takeda. C\u2019est le premier m\u00e9dicament \u00e0 agir directement sur la cause de la narcolepsie de type 1, une maladie rare qui touche environ 120 000 personnes aux \u00c9tats-Unis. Ce traitement<\/a> cible le dysfonctionnement du signal de l\u2019orexine, une prot\u00e9ine essentielle r\u00e9gissant l\u2019\u00e9veil et le sommeil.<\/p>\n

Jusqu\u2019\u00e0 pr\u00e9sent, les personnes atteintes de narcolepsie de type 1 devaient se contenter de m\u00e9dicaments att\u00e9nuant les sympt\u00f4mes, comme des stimulants pour la somnolence diurne ou des s\u00e9datifs pour les autres troubles. Orzeyful agit diff\u00e9remment : il active directement le r\u00e9cepteur OX2R dans le cerveau, reproduisant l\u2019action naturelle de l\u2019orexine. Les essais cliniques, dont les \u00e9tudes FirstLight et RadiantLight, ont montr\u00e9 que ce traitement r\u00e9duit significativement la somnolence en journ\u00e9e et les \u00e9pisodes de cataplexie (perte soudaine du tonus musculaire). Il am\u00e9liore aussi l\u2019ensemble des sympt\u00f4mes li\u00e9s \u00e0 cette maladie, qui affecte \u00e0 la fois le sommeil et le syst\u00e8me nerveux.<\/p>\n

Julie Kim, pr\u00e9sidente-directrice g\u00e9n\u00e9rale de Takeda, souligne que cette approbation marque un tournant. “C\u2019est une nouvelle classe de m\u00e9dicaments qui pourrait transformer la prise en charge de la narcolepsie de type 1 et am\u00e9liorer la qualit\u00e9 de vie des patients”, explique-t-elle.<\/p>\n

D\u2019autres laboratoires, comme Eli Lilly, investissent aussi dans cette piste th\u00e9rapeutique. En avril, Lilly a annonc\u00e9 le rachat de Centessa Pharmaceuticals pour 6,3 milliards de dollars afin de d\u00e9velopper des traitements similaires pour la narcolepsie de type 1, la narcolepsie de type 2 et l\u2019hypersomnie idiopathique. Ces avanc\u00e9es refl\u00e8tent l\u2019int\u00e9r\u00eat croissant pour les agonistes de l\u2019orexine, une approche prometteuse pour les troubles du sommeil.<\/p>\n","protected":false},"excerpt":{"rendered":"

L\u2019Agence am\u00e9ricaine des produits alimentaires et m\u00e9dicamenteux (FDA) a autoris\u00e9 la commercialisation d\u2019Orzeyful (ov\u00e9porexton), d\u00e9velopp\u00e9 par Takeda. C\u2019est le premier […]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[414],"tags":[],"class_list":["post-432","post","type-post","status-publish","format-standard","hentry","category-nouvelles"],"_links":{"self":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/comments?post=432"}],"version-history":[{"count":1,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/432\/revisions"}],"predecessor-version":[{"id":440,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/432\/revisions\/440"}],"wp:attachment":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/media?parent=432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/categories?post=432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/tags?post=432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}